Chardan Capital analyst Keay Nakae reiterated a Buy rating on Alnylam Pharmaceuticals on Wednesday, setting a price target of $190, which is approximately 6.26% above the present share price of $178.81.
Nakae expects Alnylam Pharmaceuticals to post earnings per share (EPS) of -$1.71 for the third quarter of 2021.
The current consensus among 11 TipRanks analysts is for a Moderate Buy rating of shares in Alnylam Pharma (NASDAQ:ALNY), with an average price target of $191.2.
The analysts price targets range from a high of $234 to a low of $154.
In its latest earnings report, released on 03/31/2021, the company reported a quarterly revenue of $177.57 million and a net profit of -$186.25 million. The company's market cap is $21.02 billion.
According to TipRanks.com, Chardan Capital analyst Keay Nakae is currently ranked with 5 stars on a 0-5 stars ranking scale, with an average return of 21.2% and a 45.35% success rate.
Alnylam Pharmaceuticals, Inc. operates as biopharmaceutical company, which engages in the discovery, development and commercialization of RNAi therapeutics. It is the translation of RNAi as a new class of innovative medicines with a core focus on RNAi therapeutics for the treatment of genetically defined diseases. The company was founded by John Kennedy Clarke, Paul R. Schimmel and Phillip A. Sharp (OTC:SHCAY) on June 14, 2002 and is headquartered in Cambridge, MA.